WHO study on Prevention of REcurrences of Myocardial Infarction And StrokE (WHO-PREMISE)

Bulletin of the World Health Organization

Volumn 83, Issue 11, 2005, Pages 820-828

  Mendis, Shanthi ^a   Abegunde, Dele ^a   Yusuf, Salim ^b   Ebrahim, Shah ^c   Shaper, Gerry ^d   Ghannem, Hassen ^e   Shengelia, Bakuti ^f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e FARHAT HACHED HOSPITAL   (Tunisia)

^f NONE

Author keywords

Adrenergic beta agonists therapeutic use; Angiotensin converting enzyme inhibitors therapeutic use; Aspirin therapeutic use; Cardiovascular diseases drug therapy; Cerebrovascular accident drug therapy; Myocardial ischemia drug therapy

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; DISEASE CONTROL; GLOBAL PERSPECTIVE; RISK FACTOR; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BRAZIL; CEREBROVASCULAR DISEASE; DEVELOPING COUNTRY; DIET; EGYPT; FEMALE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMOBILIZATION; INDIA; INDONESIA; IRAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PAKISTAN; PHYSICAL ACTIVITY; RECURRENT DISEASE; RISK FACTOR; RUSSIAN FEDERATION; SECONDARY PREVENTION; SMOKING CESSATION; SRI LANKA; STROKE; TUNISIA; TURKEY (REPUBLIC); WORLD HEALTH ORGANIZATION;

CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; WORLD HEALTH ORGANIZATION;

NICOTIANA TABACUM;

EID: 27744513624     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
2. Chambless L, Keil U, Dobson A, Mahonen M, Kuulasmaa K, Rajakangas AM, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation 1997;96:3849-59.
3. Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ 1998;316:838-42.
4. Royal College of Surgeons. National clinical guidelines for stroke. London: Royal College of Surgeons; 2000.
5. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Int Med 2002;162:2405-10.
6. Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions. Geneva: World Health Organization; 2002. WHO document WHO/EDM/2000.1.World Health Organization - Wellcome Trust meeting report, 1-3 August 2001.
7. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
8. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
9. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction. Arch Int Med 1999;159:561-67.
10. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease. BMJ 1998;316:1430-34.
11. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA 1995;273:1509-14.
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEJM 2000;342:145-53.
13. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711-8.
14. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 1996;335:1001-9.
15. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10.
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
17. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-8.
18. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187-95.
19. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-9.
20. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
21. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. NEJM 1992;327:669-77.
22. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103:38-44.
23. EUROASPIRE Study Group. A European Society of Cardiology survey on secondary prevention of coronary heart disease. Principal results. Eur Heart J 1997;18:1569-82.
24. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
25. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357:995-1001.
26. Steg PG, lung B, Feldman LJ, Cokkinos D, Deckers J, Fox KA, et al. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart 2002; 88:20-4.
27. Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88:15-9.
28. Ahmadi J, Khalili H, Jooybar R, Namazi N, Mohammadagaei P. Prevalence of cigarette smoking in Iran. Psychol Rep 2001;89:339-41.
29. Kromhout D, Menotti A, Kesteloot H, Sans S. Prevention of coronary heart disease by diet and lifestyle: Evidence from prospective cross cultural, cohort and intervention studies. Circulation 2002;105:893-8.
30. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2:1303-10.
31. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.
32. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280:2001-7.
33. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
34. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Prac 2002;19:596-604.
35. Van Berkel TF, Boersma H, De Baquer D, Deckers JW, Wood D. Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey. Eur Heart J 1999;20:1630-7.
36. Montaye M, De Bacquer D, De Backer G, Amouyel P. Overweight and obesity: a major challenge for coronary heart disease secondary prevention in clinical practice in Europe. Eur Heart J 2000;21:808-13.